BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Phase 2 Completed 233 enrolled Braintree Laboratories

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.

Timeline

Start: 2010-11
Primary completion: 2011-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BLI1100	Unknown	—	Topical

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Summary

Timeline

Drugs

Indications